Rhumbline Advisers Cardiff Oncology, Inc. Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
A detailed history of Rhumbline Advisers transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 42,882 shares of CRDF stock, worth $182,248. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,882
Previous 45,993
6.76%
Holding current value
$182,248
Previous $102,000
11.76%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CRDF
# of Institutions
90Shares Held
12.3MCall Options Held
813KPut Options Held
91.1K-
Black Rock Inc. New York, NY2.63MShares$11.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$9.23 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA928KShares$3.94 Million0.0% of portfolio
-
State Street Corp Boston, MA833KShares$3.54 Million0.0% of portfolio
-
Mai Capital Management663KShares$2.82 Million0.02% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $184M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...